NEO GENOMICS

Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.



NeoTYPE® Follicular Lymphoma Profile

Alternative Name
Follicular Lymphoma Profile

Methodology
FISH

Molecular

Test Description
The NeoTYPE® Follicular Lymphoma Profile analyzes 16 genes through a combination of next-generation sequencing (NGS) and FISH as noted below. Test reports include a summary interpretation of all results together. FISH components may be ordered as “Tech-Only” by pathology clients who wish to perform the professional component.

- **NGS (16 Genes):** ARID1A, BCL2, BCL6, CDKN2A, CREBBP, EP300, EZH2, FAS, KMT2D, MAP2K1, MEF2B, PIK3CA, SOCS1, STAT6, TNFAIP3, and TNFRSF14
  For EZH2, the test can detect relevant mutations in Exons 16 and 18, including Y646N, Y646H, Y646F, Y646S, Y646C, A682G, and A692V.
- **FISH probes:** IgH/BCL2 t(14;18) | DUSP22-IRF4 (6p25.3) | TNFRSF14 (1p36)

Clinical Significance
Conventional follicular lymphoma (FL) is a common form of non-Hodgkin lymphoma (NHL) that stems from germinal center B-lymphocytes and is typically characterized by diffuse lymphadenopathy, splenomegaly, and bone marrow involvement, as well as occasional involvement in other extranodal sites. Histologic grade correlates with prognosis with grade 1-2 being indolent and not usually curable. Grade 3 conventional FL has a more aggressive clinical course, but may respond to systemic therapies. Frequent recurrent genetic abnormalities in conventional FL include rearrangements of BCL2 (80%) and BCL6 (15%).

Pediatric-type follicular lymphoma (PTFL) most commonly presents in children age 7.4-14 years, but can be seen in young adults and more rarely older adults. PTFL occurs as localized disease of the head and neck lymph nodes or tonsils and is characteristically negative for BCL2 and BCL6 rearrangements. Although most cases meet conventional criteria for grade 3B FL, PTFL has a good prognosis after local excision alone. The molecular profile of PTFL differs from conventional FL, as PTFL only has rare mutations in CREBBP, EZH2 and KMT2D, which are commonly found in conventional FL. PTFL frequently has mutations in TNFRSF14 and MAP2K1. Follicular lymphoma with EZH2 mutation may respond to EZH2 inhibitors. The NeoTYPE® Follicular Lymphoma Profile has been developed to include a number of genes which are associated with lymphoma pathogenesis. Results from this test will aid in patient diagnosis, classification, prognosis, as well as treatment decisions.

Specimen Requirements
- **FFPE tissue:** Paraffin block. 10% NBF fixative is the recommended fixative. Do not use zinc or mercury fixatives (B5). Highly acidic or prolonged decalcification processes will not yield sufficient nucleic acid to accurately perform molecular studies.
- **Bone Marrow Aspirate:** 2-3 mL in EDTA tube. Molecular only. This specimen is not validated for the FISH portion.
- **Peripheral Blood:** 3-5 mL in EDTA tube. Molecular only. This specimen is not validated for the FISH portion.

Note: Test in TNA-based. Please select Extract & Hold - TNA if specimen hold service is desired.

Storage & Transportation

Refrigerate specimen. Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible.

CPT Code(s)*

81450x1; 88374x3 or 88377x3

New York Approved

No

Level of Service

Global

Turnaround Time

14 Days

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

9490 NeoGenomics Way
Fort Myers, FL 33912
Phone: 239.768.0600/ Fax: 239.690.4237
neogenomics.com

Rev. 112224